

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: AP2/18 - Antithrombotic Agents

Dead line: 14.09.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	$U_{AV}$ = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	$U_{AV}$	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>Set of samples 1</b>														
<b>(108) Apixaban</b>	[µg/L]				21							21	20	95%
Samples and groups														
<b>Sample A1</b>		202	19	9,3	21	CVP	202	10	25%	151	253	21	20	95%
(193) HYPHEN BioMed		193	27	14	11	0						11		
Other					10	0						10		
							4x 38, 4x 94, 2x 149							
<b>Sample B1</b>		422	19	4,6	21	CVP	422	10	25%	316	528	21	21	100%
(193) HYPHEN BioMed		419	22	5,3	11	0						11		
Other					10	0						10		
							4x 38, 4x 94, 2x 149							
<b>Set of samples 2</b>														
<b>(109) Dabigatran</b>	[µg/L]				26							26	26	100%
Samples and groups														
<b>Sample A2</b>		298	27	9,0	26	CVP	298	13	25%	223	373	26	26	100%
(38) IL		297	5,0	1,7	5	0						5		
(193) HYPHEN BioMed		305	21	6,8	17	0						17		
Other					4	0						4		
							4x 149							
<b>Sample B2</b>		100	12	12	26	CVP	100	5,9	25%	75	125	26	26	100%
(38) IL		103	5,0	4,9	5	0						5		
(193) HYPHEN BioMed		102	11	11	17	0						17		
Other					4	0						4		
							4x 149							
<b>Set of samples 3</b>														
<b>(110) Rivaroxaban</b>	[µg/L]				31							31	28	90%
Samples and groups														
<b>Sample A3</b>		298	28	9,5	31	CVP	298	12	25%	223	373	31	31	100%
(38) IL		269	19	7,0	7	0						7		
(193) HYPHEN BioMed		312	17	5,5	18	0						18		
Other					6	0						6		
							4x 94, 2x 149							
<b>Sample B3</b>		93,3	14	15	31	CVP	93,3	6,2	25%	69,9	117	31	28	90%
(38) IL		88,3	6,4	7,3	7	0						7		
(193) HYPHEN BioMed		99,0	17	17	18	0						18		
Other					6	0						6		
							4x 94, 2x 149							

st\_kn\_p

End of report

Printed: 20.09.2018